Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fierce Pharma
FDA's response letter salvo sheds light on drug refusal process
The FDA's response letter salvo offers an in-depth view into the high-stakes discussions that decide whether a medicine will ever make it to market.
James Waldron
,
Fraiser Kansteiner
Jul 11, 2025 10:15am
Karyopharm lays off 20% of staffers amid hunt for alternatives
Jul 11, 2025 11:02am
Relmada dumps depression asset after slew of phase 3 failures
Jul 11, 2025 12:12pm
Quest to carry Fujirebio’s FDA-cleared Alzheimer’s blood test
Jul 11, 2025 11:40am
Fierce Biotech Layoff Tracker 2025: Century, Karyopharma & more
Jul 11, 2025 10:00am
FDA rejects Capricor’s DMD cell therapy, asks for more data
Jul 11, 2025 9:18am
More News
Biopharma layoffs aren't letting up
Jul 11, 2025 8:43am
Pfizer’s reputation wrangler plans departure—Chutes & Ladders
Jul 11, 2025 8:30am
BD taps Masimo exec to lead restructured connected care group
Jul 10, 2025 1:45pm
FDA shares more than 200 CRLs for now-approved drugs
Jul 10, 2025 10:54am